眾生藥業(002317.SZ)獲得1項發明專利證書
格隆匯8月14日丨眾生藥業(002317.SZ)公佈,近日,公司收到中華人民共和國國家知識產權局頒發的發明專利證書,涉作為SMO抑制劑的喹啉衍生物。
該專利是公司用於治療小細胞肺癌、胃癌、食管癌等惡性腫瘤的創新藥物ZSP1602項目的化合物專利,屬於該項目的核心專利。該專利項目ZSP1602的“化學1類新藥ZSP1602治療晚期惡性腫瘤的I/II期臨牀研究”專項課題已被列入國家“重大新藥創制”科技重大專項,ZSP1602項目進展順利,目前正開展I期臨牀試驗。
ZSP1602項目化合物核心專利目前已獲得包括美國、新西蘭、加拿大、新加坡、日本、韓國、以色列、南非、中國等國的專利授權,ZSP1602項目的全球知識產權保護體系逐漸完善。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.